The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults

Sainz, Talíaa,*; Serrano-Villar, Sergioc,*; Díaz, Lauraa,b; Tomé, María Isabel Gonzálezd; Gurbindo, María Doloresa; de José, María Isabele; Mellado, María Joséf; Ramos, José T.g; Zamora, Javierc; Moreno, Santiagoc; Muñoz-Fernández, María Ángelesa,b

doi: 10.1097/QAD.0b013e32835faa72
Research Letters

We explored the associations of the CD4/CD8 ratio with markers of immunoactivation, immunosenescence and T-cell subsets, in 37 vertically HIV-infected children and adolescents. CD4/CD8 ratio inversion was associated with higher frequencies of activated, senescent and activated/exhausted CD4+and CD8+ T-cells, and a skewed T-cell phenotype from naive toward effector memory which persisted after the multivariate analysis. Thus, the CD4/CD8 ratio may identify patients with higher immunoactivation despite ART.

aLaboratorio de InmunoBiología Molecular y Servicio de Pediatría, Hospital General Universitario Gregorio Marañón, Madrid

bLaboratorio de InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)

cServicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, and IRYCIS

dUnidad de Inmunodeficiencias pediátricas, Servicio de Pediatría, Hospital Univeristario Doce de Octubre

eServicio de Pediatría, Hospital Univeristario La Paz

fServicio de Pediatría, Hospital Carlos III

gServicio de Pediatría, Hospital de Getafe, Madrid, Spain.

*Talía Sainz and Sergio Serrano-Villar contributed equally to the writing of this article.

Correspondence to María Angeles Muñoz-Fernández, Laboratorio de Inmunobiología Molecular, Hospital General Universitario Gregorio Marañón and CIBER BBN, C/Dr Esquerdo 46, 28007, Madrid, Spain. Tel: +34 915 290 518; fax: +34 915 290 518; e-mail:

Received 23 August, 2012

Revised 5 January, 2013

Accepted 31 January, 2013

© 2013 Lippincott Williams & Wilkins, Inc.